Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%
In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.
Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply
TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.
TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands
After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...
Open Letter: Urgent Action Necessary for Equitable Access to Bedaquiline in All Countries with High Burdens of TB, MDR-TB, and TB/HIV
TAG and 82 other organizations and 106 individuals representing TB-affected communities and civil society sent an open letter to Johnson & Johnson calling on the company...
An Activist’s Protocol Review Toolkit
An Activist’s Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols.
The ABC for a TB Activist: 1/4/6×24 Campaign and Supportive Diagnostics
On 15 June, 2023, TB Europe Coalition (TBEC) organized a webinar featuring a presentation by Treatment Action Group’s TB Project Officer, David Branigan, on the practical actions advocates can take to promote the adoption and scale up of shorter, safer 1/4/6 regimens for TB prevention and the treatment of drug-sensitive and drug-resistant TB as well as supportive diagnostics.
SMART4TB CONSORTIUM ANNOUNCES COMMUNITY PARTNERS
Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB) is a five-year cooperative agreement made possible by the United States Agency for International Development (USAID), with the assistance of the American people, that aims to transform tuberculosis (TB) prevention and care.
TAG Remarks Delivered at Multistakeholder Hearings, May, 2023
TAG prepared these remarks to deliver at multistakeholder hearings on health held on May 8 and 9, 2023, at the United Nations Headquarters in New York City.
Nitrosamines and TB Medicines Information Note and Patient FAQs
In 2020, health authorities and drug manufacturers identified a type of chemical impurity called nitrosamines in rifampicin and rifapentine, two essential medicines used in the treatment and prevention of TB. TAG and IMPAACT4TB project partners have developed several materials to…
The 1/4/6×24 Campaign Coalition Welcomes India’s Rejection of Johnson & Johnson’s Patent Evergreening Tactic
The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.